Eight pharmacokinetic genetic variants are not associated with the risk of bleeding from direct oral anticoagulants in non-valvular atrial fibrillation patients

Background: Atrial fibrillation (AF) is the leading cause of ischemic stroke and treatment has focused on reducing this risk through anticoagulation. Direct Oral Anticoagulants (DOACs) are the first-line guideline-recommended therapy since they are as effective and overall safer than warfarin in pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Campos-Staffico, Alessandra M., Dorsch, Michael P., Barnes, Geoffrey D., Zhu, Hao-Jie, Limdi, Nita A., Luzum, Jasmine A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730333/
https://www.ncbi.nlm.nih.gov/pubmed/36506510
http://dx.doi.org/10.3389/fphar.2022.1007113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9730333/
https://www.ncbi.nlm.nih.gov/pubmed/36506510
http://dx.doi.org/10.3389/fphar.2022.1007113

Ejemplares similares